Respiratory Infections

Group A streptococcal infections outbreak nearly doubles fatalities from the previous year.

Though more research is needed to determine reasons for the association, a study published in JAMA Network revealed the 2021-2022 influenza season was associated with a significantly higher household transmission risk compared to pre-pandemic seasons.

Results of a study by Yan Xie and colleagues highlight the severe impact of COVID-19, with higher death rates, increased risks of long-term complications, and greater infectivity compared to seasonal influenza.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Analysis of the NUDGE-FLU study reveals electronic nudges designed to boost influenza vaccination were more effective in older adults without diabetes, highlighting the need for tailored approaches in diabetes populations.

The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

The data from these meta-analyses highlight the value of developing systems to promote daily toothbrushing among those who have been hospitalized and, particularly, those on mechanical ventilation.

Investigational 24-valent pneumococcal conjugate vaccine developed on cell-free protein synthesis platform is first to broaden coverage without reduced immunogenicity.

The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.

Amikacin inhaled once daily for 3 days reduced risk of developing ventilator-associated pneumonia in placebo-controlled trial in critically ill.

Last year was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic.

Topline data results from the company’s phase 3 trial, STRIDE-3, were announced and will be presented at the World Vaccine Congress West Coast.

Overall, the study authors concluded that the immunogenicity of QIV and TIV was similar for common influenza ingredients for children aged 6 to 35 months.

The federal agency was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.

This discussion revolves around diagnostics for viruses and best practices and challenges.

Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.

The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.

The federal agency sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody.

The updated emergency user authorization follows similar approvals and authorizations for Moderna and Pfizer's COVID-19 vaccines.

The federal agency says the data shows immunization reduces hospitalizations by more than 57 percent in first 6 months after birth.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

The interim analysis of its phase 3 study shows the company’s mRNA-1010 vaccine was efficacious against all 4 A and B influenza strains.

Due to increased RSV activity in the southeast United States, the CDC has issued an official Health Alert Network Health Advisory. The federal agency recommends clinicians prepare to implement recently FDA-approved prevention methods.

Poll conducted by University of Michigan had a majority of people wanting to know more about it.

The vaccine is intended to help prevent lower respiratory tract disease caused by respiratory syncytial virus in infants from birth to 6 months of age.

With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.

A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.

The lawsuit comes as the RSV market is likely to get more crowded, with a pending approval for Pfizer's pediatric indication later this month and a BLA submission from Moderna recently filed.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) also added the recently approved therapeutic to the Vaccines for Children program.